|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The apolipoprotein B/apolipoprotein A-I (ApoB/ApoA-I) and insulin resistance has been recognized as common cardiovascular diseases (CVD) risk factors.
|
31753787 |
2020 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Fasting Apolipoprotein B48 (ApoB48) is reported to be a well surrogate marker for postprandial lipidemia and have been repeatedly associated with cardiovascular disease.
|
30842592 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Intraindividual (or 'visit-to-visit') variability of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglyceride have all been found to associate with CVD outcomes, independent of their mean absolute levels, independent of each other, and independent of other traditional risk factors.
|
31045584 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lowering apolipoprotein B secretion from HepG2 cells and decreasing the level of low-density lipoprotein (LDL)-cholesterol oxidation are mechanisms related to the prevention of cardiovascular diseases (CVD).
|
31146372 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To compare the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) gene and LDL-C-lowering variants in the LDL receptor gene (LDLR) with the risk of cardiovascular disease per unit change in ApoB.
|
30694319 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids.
|
30688048 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The high prevalence of short sleep duration and its strong association with elevated apoB in adults who are metabolically unhealthy overweight/obese suggest an increased risk of cardiovascular disease in this population.
|
30755447 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Recent evidence underscores the importance of LDL-C lowering in CVD prevention by mechanisms that increase the hepatic clearance of apolipoprotein B-containing lipoproteins from the plasma.
|
31227914 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
|
31642874 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipid-lowering medications can attenuate anti-inflammatory medication-induced increases in ApoB and LDL-C, but can also reduce CVD risk due to cumulative lifetime exposure.
|
31145122 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
In addition, BA lowers levels of non-high-density lipoprotein cholesterol, C-reactive protein, and apolipoprotein B. Statins are first-line agents for primary and secondary prevention of cardiovascular disease.
|
29939848 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoproteins containing apolipoprotein B modify associations of elevated urinary albumin excretion (UAE) with cardiovascular disease (CVD).
|
30813431 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
And some researches have already studied that Apolipoprotein B to Apolipoprotein A1 ratio (ApoB/ApoA1) and Triglyceride to High-density lipoprotein cholesterol ratio (TG/HDL-C) were both related with CVD and NAFLD, but few studied the association between TC/HDL-C ratio and NAFLD.
|
30744645 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Fasting blood glucose, diastolic blood pressure, and body mass index significantly decreased with almond consumption of >42.5 g compared with ≤42.5 g. Almond consumption may reduce the risk of CVD by improving blood lipids and by decreasing body weight and apoB.
|
31243439 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Previous reports have indicated that low autoantibody levels against apolipoprotein B-100 (apo B-100) could increase the risk of atherosclerotic cardiovascular diseases (CVD) in healthy subjects.
|
30867375 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The reduction of plasma apolipoprotein B (apoB) containing lipoproteins has long been pursued as the main modifiable risk factor for the development of cardiovascular disease (CVD).
|
31472752 |
2019 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
These findings show that APOB p18-specific CD4<sup>+</sup> T cells are mainly Tregs in healthy donors, but coexpress other CD4 lineage transcription factors in donors with subclinical cardiovascular disease.
|
29588316 |
2018 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population.
|
28992985 |
2018 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
These included proteins already studied in the context of CVD (such as apolipoprotein B, alpha-2-macroglobulin), as well as novel findings (such as low density lipoprotein receptor related protein 2 [LRP2], protein SZT2) for which a mechanism of action is suggested.
|
29665821 |
2018 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant hypercholesterolemia (ADH), characterized by high-plasma low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease (CVD) risk, is caused by mutations in LDLR, APOB, and/or PCSK9.
|
27919364 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Postprandial triglycerides, TG-rich lipoprotein triglycerides, retinyl palmitate and apolipoprotein B48 to B100 ratio were measured before (following a 12-hour fasting period) and after a fat-tolerance test meal in a middle-aged, biracial subcohort without CVD (coronary heart disease (CHD) or stroke) from the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990-1993.
|
28191321 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
A thorough evaluation of clinical data by the expert working group resulted in recommendations to consider non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB), remnant cholesterol and lipoprotein(a) (Lp[a]) as biomarkers of residual CV risk in patients with CVD.
|
28434480 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Enzyme-Linked Immunoassay-Based Quantitative Measurement of Apolipoprotein B (ApoB) in Dried Blood Spots, a Biomarker of Cardiovascular Disease Risk.
|
28521623 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Apolipoprotein A-I (ApoA-I) and apolipoprotein B-100 (ApoB-100) are amphipathic proteins that are strong predictors of cardiovascular disease risk.
|
28296203 |
2017 |